NKF(SH:603707)2024-04-26 14:21Financial Performance - The company's operating revenue for 2023 was CNY 3,931,387,279.72, representing a year-on-year increase of 5.89% compared to CNY 3,712,720,455.00 in 2022[20]. - The net profit attributable to shareholders of the listed company for 2023 was a loss of CNY 189,445,790.76, a decrease of 117.37% compared to a profit of CNY 1,090,833,203.91 in 2022[20]. - The basic earnings per share for 2023 was -CNY 0.12, down 117.91% from CNY 0.67 in 2022[21]. - The weighted average return on equity for 2023 was -3.17%, a decrease of 21.99 percentage points from 18.82% in 2022[21]. - The net assets attributable to shareholders of the listed company at the end of 2023 were CNY 5,801,966,942.85, a decrease of 5.97% from CNY 6,170,641,484.29 at the end of 2022[20]. - The total assets at the end of 2023 were CNY 9,524,263,988.46, down 4.85% from CNY 10,010,102,945.14 at the end of 2022[20]. - The company reported a significant impact on profits due to changes in the heparin industry, leading to inventory impairment provisions[22]. - The company recorded non-operating income of CNY 54,909,397.90 from government subsidies in 2023, compared to CNY 11,266,909.39 in 2022[26]. - The company experienced a loss of CNY 91,741,525.04 from fair value changes of financial assets and liabilities in 2023, compared to a gain of CNY 624,613.67 in 2022[26]. Research and Development - Research and development (R&D) investment reached RMB 59,064.12 million, representing 15.02% of operating revenue, an increase of 89.53% compared to the previous year[30]. - The company has over 500 R&D personnel, including more than 100 with master's or doctoral degrees[54]. - The company operates three major R&D centers in Nanjing, Chengdu, and the United States, enhancing R&D efficiency and reducing costs[54]. - The company is expanding its R&D strategy to include oncology, immunomodulation, and nucleic acid drugs[55]. - The company has developed advanced platforms for peptide drugs and complex formulations, enhancing its product development capabilities[56]. - The company is committed to maintaining a strong R&D pipeline, with a focus on innovative therapies and regulatory approvals to enhance market presence[99]. - The company received multiple product approvals in 2023, including Nalbuphine Injection in the US in January and Gemcitabine Hydrochloride Injection in China in April[106]. Market Expansion - The company is focused on expanding its presence in the international pharmaceutical market[4]. - The company is actively expanding into over 20 countries, including regions in South America, Central America, Central Asia, West Asia, and North Africa, to enhance its global market presence[34]. - The company plans to further develop its product pipeline in the U.S. market, which is expected to enhance sales scale and profitability[34]. - The company achieved a record high in CDMO project numbers during the reporting period, with continuous revenue growth from CDMO services, successfully assisting nearly ten innovative projects to enter clinical trials[35]. - The company is exploring partnerships with other firms to leverage synergies in technology and market access[144]. Corporate Governance - The board of directors and supervisory board members have confirmed the authenticity, accuracy, and completeness of the annual report[4]. - The company ensured compliance with information disclosure regulations, providing timely and accurate information to shareholders[138]. - The company has established a dedicated department for investor relations to enhance communication with minority shareholders[138]. - The company’s governance structure aligns with the requirements of the Company Law and the Securities Law, ensuring effective decision-making processes[135]. - The company has not reported any significant differences in governance practices compared to regulatory requirements[135]. Environmental Responsibility - The company is committed to sustainability and plans to implement eco-friendly practices in its manufacturing processes, aiming for a 50% reduction in carbon emissions by 2025[41]. - The company has not faced any penalties for major violations during the reporting period, reflecting its commitment to environmental responsibility[180]. - The company has established emergency response plans for environmental incidents, which have been filed with the relevant authorities[189]. - The company has implemented carbon reduction measures, resulting in a decrease of 1,427.42 tons of CO2 equivalent emissions[196]. - The company has installed online monitoring equipment for COD, ammonia nitrogen, total phosphorus, and pH at the wastewater discharge outlet[191]. Financial Management - The company plans to increase the use of idle funds for cash management, indicating a strategy to optimize financial resources[152]. - The company is actively engaging in foreign exchange hedging business, indicating a proactive approach to managing currency risk[152]. - The company has established strict systems and approval processes to manage risks associated with derivative investments[119]. - The company has a robust evaluation mechanism for senior management, linked to performance and incentive policies[174]. Product Development - The company is actively involved in the research and development of new drugs and technologies to enhance its market position[92]. - The company is focusing on expanding its product offerings in the anticoagulant and oncology markets, which have substantial growth potential[90]. - The company has established a product R&D pipeline for biopharmaceuticals through both collaborative and independent research efforts[128]. Shareholder Engagement - The company distributed a cash dividend of 0.115 yuan per share, totaling 185,914,598.66 yuan, approved on May 19, 2023[169]. - The total remuneration received by the board of directors, supervisors, and senior management during the reporting period amounted to CNY 4.413 million[148]. - Major shareholders have committed to not interfering with the company's management activities and to uphold measures for compensating diluted returns[199].